S2035
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Bill overview
This bill proposes to eliminate the tax deduction currently available to pharmaceutical companies for marketing their products directly to consumers. The goal is to reduce the financial incentives for promoting prescription drugs to individuals rather than healthcare providers. By removing this deduction, the state aims to shift the focus towards more responsible and evidence-based healthcare decisions. This legislation seeks to address concerns about the influence of direct-to-consumer advertising on pharmaceutical sales and patient choices.
Key provisions
- Eliminates the tax deduction for direct-to-consumer pharmaceutical marketing.
- Applies to all pharmaceutical companies operating within the state.
- Seeks to reduce the financial incentives for promoting prescription drugs to consumers.
- Aims to shift the focus of pharmaceutical marketing towards healthcare professionals.
- The bill is intended to generate revenue for the state.
Who is affected
- Pharmaceutical companies
- Healthcare providers
- Consumers
- The State of Massachusetts
Notable changes
- This bill represents a significant change in state policy regarding pharmaceutical marketing.
- It mirrors previous attempts to address this issue through legislation.
- The elimination of the tax deduction could impact pharmaceutical company budgets and marketing strategies.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Jason M. Lewis
Cosponsors
Jason M. Lewis
Rebecca L. Rausch
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
Bill S.2035 194th (Current)
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
By Mr. Lewis, a petition (accompanied by bill, Senate, No. 2035) of Jason M. Lewis and Rebecca L. Rausch for legislation to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing. Revenue.
View Text Print Preview Download PDF
Bill Information
Bill Information
Presenter: Jason M. Lewis Status: Referred to Joint Committee on Revenue
Tabs
Bill History Petitioners Primary Sponsor Summary
Bill History
Displaying 4 actions for Bill S.2035
| Date | Branch | Action |
| 2/27/2025 | Senate | Referred to the committee on Revenue |
| 2/27/2025 | House | House concurred |
| 10/21/2025 | Joint | Hearing scheduled for 10/28/2025 from 01:00 PM-05:00 PM in B-2 |
| 4/1/2026 | Senate | Reporting date extended to Thursday June 25, 2026 |
Similar Bills
S.1915 192nd (2021 - 2022)
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
S.1862 193rd (2023 - 2024)
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
S.1508 189th (2015 - 2016)
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
S.1558 190th (2017 - 2018)
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
S.1701 191st (2019 - 2020)
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.